【罂粟摘要】普瑞巴林对糖尿病神经痛患者的心率变异性影响

贵州医科大学  麻醉与心脏电生理课题组

翻译：刘云琴   编辑：潘志军   审校：曹莹

摘要：许多研究表明，低心率变异性（HRV）是心血管疾病患者高死亡率和高发病率的一个风险因素  。本研究的主要目的是评估普瑞巴林是否能改善糖尿病周围神经痛患者的HRV。在基线和对糖尿病周围神经痛患者进行为期4周的普瑞巴林或安慰剂干预后，使用由VivoMetrics（Ventura，Calif）开发的Lifeshirt系统收集静息心率。使用LifeShirt系统的Vivo-VMLA-036-00 3对收集的R-R间期进行心率变异性分析。在参与该研究的40名患者中，70%完成了4周的评估（普瑞巴林组15名，安慰剂组14名）。与安慰剂相比，普瑞巴林治疗显著改善了频域分析测得的HRV，即降低了低频高频比(-1.30±2.89vs 0.37±0.33,P=0.03）和归一化低频功（-0.049±0.092vs0.0066±0.023,P=0.02），以及归一化高频功率增加（0.039±0.094vs-0.038±0.066,P=0.02）。此外，普瑞巴林能更大程度地减轻疼痛和焦虑症状，提高生活质量。HRV测量值的改善与这些测量值的变化无关。总之，4周普瑞巴林治疗改善了 糖尿病周围神经痛患者的HRV。                                                                                        

原始文献来源：

Jiang Wei,Ladd Shelby,Martsberger Carolyn et al. Effects of pregabalin on heart rate variability in patients with painful diabetic neuropathy.[J] .J Clin Psychopharmacol, 2011, 31: 207-13.

Effects of Pregabalin on Heart Rate Variability in Patients With Painful Diabetic Neuropathy

Abstract:

Many studies have demonstrated that low heart rate variabi-lity (HRV) is a risk for high mortality and morbidity in patients withcardiovascular diseases. The primary purpose of the study was to evaluatewhether pregabalin improves HRV in patients with diabetes and painfulperipheral neuropathy. Resting heart rates were collected by using theLifeShirt System, developed by VivoMetrics (Ventura, Calif), at baselineand at the end of a 4-week intervention of pregabalin or placebo in patientswith painful diabetic peripheral neuropathy. Heart rate variability analysiswas performed on the collected R-R intervals using the Vivo- VMLA-036-00 3 Logic of the LifeShirt system. Of the 40 patients enrolled in the study,70% completed the end of 4-week assessments (n = 15 in pregabalin andn = 14 in placebo). Compared with placebo, pregabalin treatment resultedin significant improvement in HRV measured by frequency domain anal-ysis, that is, a reduction in low frequency-high frequency ratio (j1.30T2.89 vs 0.37T0.33,P= 0.03) and power of normalized low frequency(j0.049T0.092 vs 0.0066T0.023,P= 0.02), as well as an increase inpower of normalized high frequency (0.039T0.094 vsj0.038T0.066,P= 0.02). Furthermore, pregabalin resulted in greater reduction of painand symptoms of anxiety and greater improvement of quality of life.The improvement of HRV measures were not correlated with change ofthose measures. In conclusion, 4-week pregabalin treatment improvedHRV in patients with painful diabetic peripheral neuropathy.